November 7, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 2 November 2022, Paul Pagano, Chief Executive […]
• Read MoreOctober 17, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) LungLife to participate in the US National Cancer Institute’s Early Detection Research Network LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that based on the strength of its technology it will be one of two industry partners to participate in the Boston […]
• Read MoreSeptember 26, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2022. Summary and Highlights (including post-period end): Cash as of 30 June 2022 of $10.63m Loss before […]
• Read MoreSeptember 9, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, will announce its interim results for the six months ended 30 June 2022 on Monday 26 September 2022. Investor presentation Paul Pagano, Chief Executive Officer, and David […]
• Read MoreSeptember 2, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) New York State approves LungLB® for commercial testing LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the New York State Department of Health (“NYSDOH”) has awarded LungLife a Clinical Laboratory Evaluation Program (“CLEP”) permit following their recent on-site audit, during […]
• Read MoreMay 16, 2022
16 May 2022 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of […]
• Read MoreMay 11, 2022
LungLife AI, Inc. (the “Company” or “LungLife”) Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting, held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a […]
• Read MoreMay 9, 2022
The Annual General Meeting of LungLife AI,Inc. the “Company”) to be held at 2:00 p.m. BST on 11 May 2022 at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, United Kingdom (including any adjournment or postponement thereof, the “AGM”). Stockholders will be able to listen live to the AGM by accessing the below Microsoft […]
• Read MoreApril 8, 2022
8 April 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
• Read MoreMarch 28, 2022
28 March 2022 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary results LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its maiden audited preliminary results for the year ended 31 December 2021, following admission to trading on AIM on 8 July 2021. Summary and Highlights for the year: Revenues […]
• Read More
LungLife AI licensure/accreditation information posted here.